|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Shave biopsy and immunohistochemical studies revealed that the tumor was composed of malignant melanoma (MM) (highlighted by S100 and MART-1) intermixed with squamous cell carcinoma (SCC) (highlighted by cytokeratin and p63), and a diagnosis of combined MM-SCC was rendered.
|
31361351 |
2020 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
S100, human melanoma black 45, and melanoma antigen recognized by t-cell (Melan A) were negative.
|
30978337 |
2020 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although immunohistochemical (IHC) stains such as HMB45, Melan A, and S-100 are often utilized; the role of Sry-related HMG-box gene 10 (SOX10) in the diagnosis of melanoma in effusions has not been previously reported.
|
30794352 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
On histopathological and immunohistochemical analysis with S-100 and homatropine methylbromide 45 the diagnosis of MM was confirmed.
|
31154344 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In all cases, immunohistochemistry of the cartilaginous component was positive for S-100, which is not an indicator of melanoma because cartilage expresses S-100.
|
31260118 |
2019 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It can be measured in cerebrospinal fluid and in blood, and increased S100B level in blood can be seen after, e.g., traumatic brain injury, certain neurodegenerative disorders, and malignant melanoma.
|
30710304 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to explore the potential uses of serum S100B protein as a biomarker in melanoma patients.
|
29135116 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum S100B Levels in Melanoma.
|
30710305 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeted S100 therapies are also potentially viable strategies in the context of melanoma.
|
30216200 |
2019 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We studied cytokine profile of cellular Th1 (IL-2, IL-12, IFN-γ) and humoral Th2 (IL-4, IL-10) immune response, vascular endothelial growth factor (VEGFA), transforming growth factor-β 2 (TGF-β 2), S100 protein (S100A1B and S100BB), adhesion molecule CD44 and serum cytokines β2-microglobulin to analyze different peripheral blood mononuclear cell subpopuations of patients treated with dendritic vaccines and/or cyclophosphamide in melanoma patients in the course of adjuvant treatment.
|
29849947 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
S100B belongs to the S100 family and serum S100B (also known as S100beta) serves as a marker for metastasis in lung cancer, ovarian cancer and melanoma.
|
29345293 |
2018 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A dural biopsy was done which showed sheets of poorly differentiated tumor cells which expressed S100 and Melan A and were immunoreactive with Human Melanoma Black (HMB)-45 antibody, consistent with the diagnosis of malignant melanoma.
|
29876986 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The tumour cells were positive for melanocytic markers, including S100 and Human Melanoma Black 45, which led to an initial diagnosis of malignant melanoma.
|
29072181 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accumulating evidence over the past few decades has highlighted the potential use of circulating molecular biomarkers for melanoma diagnosis and prognosis, including lactate dehydrogenase (LDH), S100 calcium-binding protein B (S100B) and circulating tumor DNA (ctDNA) fragments.
|
29701682 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Common histopathologic features are melanic pigment (<i>n</i> = 19/20), positive Human Melanoma Black (HMB-45) marker (<i>n</i> = 13/20), positive S100 protein reactivity (<i>n</i> = 11/20), as well as positive Melan-A (<i>n</i> = 9/20).
|
29649851 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the use of S100B as a biomarker in melanoma is well established, to our knowledge its association with vitiligo activity has not yet been investigated.
|
28212812 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
|
27633490 |
2017 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Common markers used to identify melanoma cell lines include: S100; HMB-45; and Melan-A.
|
27087056 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated LDH is a BRAF-independent prognostic parameter; S100B has prognostic significance in BRAFwt melanoma only.
|
26659191 |
2016 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, the 'MELmiR-7' panel characterised overall survival of melanoma patients better than both serum LDH and S100B (delta log likelihood = 11, p < 0.001).
|
26288839 |
2015 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Comparative genomic hybridization in a case of melanoma that loses expression of S100, HMB45, Melan A and tyrosinase in metastasis.
|
24427375 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, elevated S100B contributes to abnormal ERK/RSK signaling and increased cell survival in malignant melanoma.
|
24627490 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
S100 remains as the most reliable routine marker to reach the diagnosis of melanoma in spindle cell and desmoplastic melanoma.
|
24051699 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The S100B protein, which is clinically used as the pathology identifier of MM, was identified in 9 out of 10 MM tissue lysates.
|
24490776 |
2014 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The interaction between human S100 calcium-binding protein B (S100B) and the tumor suppressor protein p53 is considered to be a possible therapeutic target for malignant melanoma.
|
23375094 |
2013 |